
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
Keywords: کارآزمایی بالینی; Bispecific antibodies; Clinical trial; Gastrointestinal cancer; Pancreatic cancer; Pharmacokinetics;